Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery. Issue 13 (20th June 2019)

• Record Type: Journal Article
• Authors: Vaughan, Hannah J.; Green, Jordan J.; Tzeng, Stephany Y.
• Is Part Of: Advanced materials. Volume 32:Issue 13(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-06-20
• Subjects: cancer therapy -- gene delivery -- nanoparticles -- nucleic acid -- targeted delivery; Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adma.201901081
• Languages: English
• ISSNs: 0935-9648

Abstract

Abstract: Nucleic acids are a promising type of therapeutic for the treatment of a wide range of conditions, including cancer, but they also pose many delivery challenges. For efficient and safe delivery to cancer cells, nucleic acids must generally be packaged into a vehicle, such as a nanoparticle, that will allow them to be taken up by the target cells and then released in the appropriate cellular compartment to function. As with other types of therapeutics, delivery vehicles for nucleic acids must also be designed to avoid unwanted side effects; thus, the ability of such carriers to target their cargo to cancer cells is crucial. Classes of nucleic acids, hurdles that must be overcome for effective intracellular delivery, types of nonviral nanomaterials used as delivery vehicles, and the different strategies that can be employed to target nucleic acid delivery specifically to tumor cells are discussed. Additonally, nanoparticle designs that facilitate multiplexed delivery of combinations of nucleic acids are reviewed. Abstract : Synthetic nanoparticles can be used for delivery of combinations of nucleic acid, with different materials conferring different advantages for safe and effective delivery. Targeting strategies can also be employed for cancer‐specific delivery, including passive targeting based on nanoparticle physical properties; active targeting using cancer‐specific ligands; transcriptional targeting using cancer‐specific promoters; and targeting of cancer‐specific proteins or signaling pathways.